EcoDrugPlus

Protein Kinase C Zeta

Ensembl ID : ENSLACG00000014522
Gene Symbol: PRKCZ
3 Cross references
201 Possible Orthologues:

Protein Kinase D1

Ensembl ID : ENSLACG00000005649
Gene Symbol: PRKD1
3 Cross references
204 Possible Orthologues:

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSLACG00000014083
Gene Symbol: PRKDC
3 Cross references
184 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSLACG00000001093
Gene Symbol: PPP3CA
4 Cross references
233 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSLACG00000011204
Gene Symbol: PTK2
2 Cross references
334 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSLACG00000000159
Gene Symbol: PTK2B
2 Cross references
269 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSLACG00000006352
Gene Symbol: PTPN11
4 Cross references
251 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSLACG00000003463
Gene Symbol: PTPRB
2 Cross references
264 Possible Orthologues:

Proteinase-Activated Receptor 3-Like

Ensembl ID : ENSLACG00000007932
Gene Symbol: LOC102357829
3 Cross references
193 Possible Orthologues:

Proteinase-Activated Receptor 3-Like

Ensembl ID : ENSLACG00000000072
Gene Symbol: LOC102353789
3 Cross references
193 Possible Orthologues:

Proteinase-Activated Receptor 4-Like

Ensembl ID : ENSLACG00000012866
Gene Symbol: LOC102359410
3 Cross references
10 Possible Orthologues:

Purinergic Receptor P2x 3

Ensembl ID : ENSLACG00000004266
Gene Symbol: P2RX3
4 Cross references
270 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).